SCHEMBL5994786

SCHEMBL5994786

CCN(C(=O)c1ccc(Nc2ncc(NC(=O)c3ccc(O)cc3Cl)cn2)cc1)N1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.40
▸ LCK P06239 7/20 0.40
▸ MAPK14 Q16539 7/20 0.40
▸ KDR P35968 4/20 0.40
▸ BLK P51451 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ SRC P12931 2/20 0.37
▸ PABPC1 P11940 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5996066 0.93 LCK (0.45) LCKMAPK14KDRBLKBTK
SCHEMBL5998218 0.88 BTK (0.39) LCKMAPK14KDRBLKBTK
SCHEMBL5996933 0.84 LCK (0.58) LCKMAPK14KDRBTKAURKA
SCHEMBL5999306 0.82 LCK (0.42) LCKMAPK14KDRBLKBTK
SCHEMBL5997433 0.79 LCK (0.45) LCKMAPK14KDRBLKBTK
SCHEMBL2499026 0.79 BTK (0.62) LCKMAPK14KDRBLKBTK
SCHEMBL5995525 0.79 LCK (0.43) LCKMAPK14KDRBLKBTK
SCHEMBL5994762 0.79 ABL1 (0.53) ALDH1A1ABL1AURKAAURKBSRC
SCHEMBL5996242 0.76 ALDH1A1 (0.48) LCKMAPK14KDRHPGDALDH1A1
SCHEMBL2495023 0.75 BTK (0.69) LCKMAPK14KDRBLKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060247250-A1 Pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247250-A1 Pyrimidine inhibitors of kinases DTYMK, SRC, DCK HSD11B1 4457/4885LCK 4/4885MAPK14 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback